MyOme, Inc.

MyOme, Inc. is a clinical whole genome analysis platform company headquartered in Menlo Park, California. The company's mission is to combine whole genome sequencing with cutting-edge bioinformatics to make meaningful genetics-driven insights the standard of care. Founded in 2017, MyOme aims to empower individuals and health systems to understand and proactively manage their genetic risks.

MyOme provides comprehensive genomic sequencing (whole genome sequencing - WGS) and advanced analytics to deliver actionable reports. These offerings include Proactive Health tests, which provide insights on single-gene risks, medication responses, and integrated polygenic risk scores for conditions such as coronary artery disease, breast cancer, and type 2 diabetes. Additionally, MyOme offers Diagnostic tests, including Rare Disease Exome, Rare Disease Genome, and Rare Disease Copy Number Analysis, to help identify genetic causes of undiagnosed conditions. The company also provides complimentary access to genetic counseling to support patients and providers in understanding and acting on their results.

Recent developments highlight MyOme's growth and strategic partnerships. In November 2025, the company launched its Proactive Health Network, a national platform for concierge and executive health clinics focused on proactive health management. MyOme also partnered with Collective Health in May 2025 to expand access to its whole-genome based products for employers and collaborated with Ms.Medicine in December 2025 to integrate genomics into routine primary care. Premal Shah serves as CEO, and Matthew Rabinowitz is the Chairman and Co-Founder. In April 2026, MyOme strengthened its Board of Directors with the appointment of Sam Roosz and Dr. Ravi Thadhani. Furthermore, Illumina made a strategic investment and partnered with MyOme in December 2025 to advance MyOme's Proactive Health (MPH) Trial, aiming to demonstrate improved patient outcomes and cost savings through whole-genome sequencing and AI-integrated risk models.